Tucatinib Continuation Study
← catalyst calendarNCT07768358 · readout in 2,032 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 4
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
175estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-24 | estimated | When the study began enrolling |
| Primary completion | 2032-03-13 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-03-13 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- HER2-positive Breast Cancer
- Cervical Cancer
- Biliary Tract Neoplasms
- Urothelial Cancer
- Advanced Non-Small Cell Lung Cancer
- Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
- Colorectal Cancer
Intervention
- Drug: tucatinib — also filed as TUKYSA
Primary outcome
what the primary-completion date above is the date OFTo monitor the safety and tolerability of tucatinib
measured Up to approximately 5 years
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed